Identifying cut points for biomarker defined subset effects in clinical trials with survival endpoints

Contemporary Clinical Trials

Volumn 38, Issue 2, 2014, Pages 333-337

  He, Pei ^a  

^a AMGEN INC   (United States)

Author keywords

Biomarker; Change points; Clinical trials; Cox proportional models; Subset selection; Survival endpoints

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BLOOD PRESSURE; CHANGE POINT; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SEQUENTIAL ANALYSIS; SIMULATION; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE; SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; BIOASSAY; CLINICAL TRIAL; METHODOLOGY; STATISTICAL MODEL;

BIOLOGICAL MARKERS; ENDPOINT DETERMINATION; HUMANS; MODELS, STATISTICAL; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN;

EID: 84903445433     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2014.06.005     Document Type: Article

References (16)

1. Jonker D.J., O'Callaghan C.J., Karapetis C.S., Zalcberg J.R., Tu D., Au H., et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007, 357:2040-2048.
2. Eberhard D.A., Johnson B.E., Amler L.C., Goddard A.D., Heldens S.L., Herbst R.S., et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23:5900-5909.
3. Mazumdar M., Glassman J.R. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. Stat Med 2000, 19:113-132.
4. Lausen B., Schumacher M. Evaluating the effect of optimized cutoff values in the assessment of prognostic factors. Comput Stat Data Anal 1996, 21:307-326.
5. Altman D.G., Lausen B., Sauerbrei W., Schumacher M. Dangers of using optimal cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994, 86:829-835.
6. Abdolell M., LeBlanc M., Stephens D., Harrison R.V. Binary partitioning for continuous longitudinal data: categorizing a prognostic variable. Stat Med 2002, 21:3395-3409.
7. Hilsenbeck S.G., Clark G.M. Practical p-value adjustment for optimally selected cutpoints. Stat Med 1996, 15:103-112.
8. Hilsenbeck S.G., Clark G.M., McGuire W.L. Why do so many prognostic factors fail to pan out?. Breast Cancer Res Treat 1992, 22:197-206.
9. Miller R., Siegmund D. Maximally selected chi square statistics. Biometrics 1982, 38:1011-1016.
10. Su M., Fang L., Su Z. A likelihood and resampling based approach to dichotomizing a continuous biomarker in medical research. J Biopharm Stat 2013, 23:637-647.
11. Wang R., Lagakos S.W., Ware J.H., Hunter D.J., Drazen J.M. Statistics in medicine - reporting of subgroup analyses. clinical trials 2007, 357:2189-2194.
12. Pettitt A.N. A simple cumulative sum type statistic for the change-point problem with zero-one observations. Biometrika 1980, 67:79-84.
13. James B., James K.L., Siegmund D. Test for a change point. Biometrika 1987, 74:71-83.
14. Zhang N.R., Siegmund D. A modified Bayes information criterion with applications to the analysis of comparative genomic hybridization data. Biometrics 2007, 63:22-32.
15. He P., Kong G., Su Z. Estimating the survival functions for right-censored and interval-censored data with piecewise constant hazard functions 2013, 35:122-127.
16. Cox D.R. Regression models and life-tables. J R Stat Soc Ser B Methodol 1972, 34:187-220.